Lexaria Bioscience Corp. (LEXX) vs MetaVia Inc. (MTVA)

Lexaria Bioscience Corp. and MetaVia Inc. are both Biotechnology companies. Lexaria Bioscience Corp. is the larger, with a market value of $8.8M against $7.2M — 1.2× the size. Across the 9 metrics below, Lexaria Bioscience Corp. leads on 5 and MetaVia Inc. on 4.

Valuation

Metric LEXX MTVA Biotechnology median
P/E n/m n/m 10.26
P/S 12.64 n/m 9.18
P/B 1.58 0.92 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 0.17 0.65
EV/Sales 6.08 n/m 8.98
Earnings yield (126.07%) (377.38%) (34.89%)
Free cash flow yield (109.89%) (251.86%) (24.52%)

Profitability

Metric LEXX MTVA Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (162.60%) (175.68%) (50.12%)
Return on assets (134.20%) (91.06%) (45.60%)
Return on invested capital (662.56%) 0.00% 0.00%

Growth

Metric LEXX MTVA Biotechnology median
Revenue growth (TTM) 9.08% — 6.26%
EPS growth (last fiscal year) (40.43%) 81.23% 29.88%
Revenue growth, 5-year CAGR 17.53% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LEXX MTVA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.60 2.06 4.89
Net debt to EBITDA 0.17 0.75 1.01

Dividend

Metric LEXX MTVA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LEXX MTVA Biotechnology median
Market cap 8.78m 7.18m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack